Insys Therapeutics

Insys Therapeutics

Pharmaceuticals, 444 South Ellis Road, Chandler, Arizona, 85224, United States, 201-500 Employees

insysrx.com

  • facebook
  • LinkedIn

phone no Phone Number: 60********

Who is INSYS THERAPEUTICS

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and D...

Read More

map
  • 444 South Ellis Road, Chandler, Arizona, 85224, United States Headquarters: 444 South Ellis Road, Chandler, Arizona, 85224, United States
  • 1998 Date Founded: 1998
  • 201-500 Employees: 201-500
  • dollar-icon Revenue: $50 Million to $100 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from INSYS THERAPEUTICS

Insys Therapeutics Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Insys Therapeutics

Answer: Insys Therapeutics's headquarters are located at 444 South Ellis Road, Chandler, Arizona, 85224, United States

Answer: Insys Therapeutics's phone number is 60********

Answer: Insys Therapeutics's official website is https://insysrx.com

Answer: Insys Therapeutics's revenue is $50 Million to $100 Million

Answer: Insys Therapeutics's SIC: 2834

Answer: Insys Therapeutics's NAICS: 325412

Answer: Insys Therapeutics has 201-500 employees

Answer: Insys Therapeutics is in Pharmaceuticals

Answer: Insys Therapeutics contact info: Phone number: 60******** Website: https://insysrx.com

Answer: Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access